Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2
By Xi Xu, Chengcheng Yu, Jing Qu, Lie-guang Zhang, Song-feng Jiang, Deyang Huang, Bi-hua Chen, Zhi-ping Zhang, W. Guan, Zhoukun Ling and 8 more. European Journal of Nuclear Medicine and Molecular Imaging, 2020
719 citations recorded by the source corpus.
Background The pneumonia caused by the 2019 novel coronavirus (SARS-CoV-2, also called 2019-nCoV) recently break out in Wuhan, China, and was named as COVID-19. With the spread of the disease, similar cases have also been confirmed in other regions of China. We aimed to report the imaging and clinical characteristics of these patients infected with SARS-CoV-2 in Guangzhou, China. Methods All patients with laboratory-identified SARS-CoV-2 infection by real-time polymerase chain reaction (PCR) were collected between January 23, 2020, and February 4, 2020, in a designated hospital (Guangzhou Eighth People’s Hospital). This analysis included 90 patients (39 men and 51 women; median age, 50 years (age range, 18–86 years). All the included SARS-CoV-2-infected patients underwent non-contrast enhanced chest computed tomography (CT). We analyzed the clinical characteristics of the patients, as well as the distribution characteristics, pattern, morphology, and accompanying manifestations of lung lesions. In addition, after 1–6 days (mean 3.5 days), follow-up chest CT images were evaluated to assess radiological evolution. Findings The majority of infected patients had a history of exposure in Wuhan or to infected patients and mostly presented with fever and cough. More than half of the patients presented bilateral, multifocal lung lesions, with peripheral distribution, and 53 (59%) patients had more than two lobes involved. Of all included patients, COVID-19 pneumonia presented with ground glass opacities in 65 (72%), consolidation in 12 (13%), crazy paving pattern in 11 (12%), interlobular thickening in 33 (37%), adjacent pleura thickening in 50 (56%), and linear opacities combined in 55 (61%). Pleural effusion, pericardial effusion, and lymphadenopathy were uncommon findings. In addition, baseline chest CT did not show any abnormalities in 21 patients (23%), but 3 patients presented bilateral ground glass opacities on the second CT after 3–4 days. Conclusion SARS-CoV-2 infection can be confirmed based on the patient’s history, clinical manifestations, imaging characteristics, and laboratory tests. Chest CT examination plays an important role in the initial diagnosis of the novel coronavirus pneumonia. Multiple patchy ground glass opacities in bilateral multiple lobular with periphery distribution are typical chest CT imaging features of the COVID-19 pneumonia.
Subfields: Dermatology, Infectious Diseases, Neurology
View Paper: https://www.semanticscholar.org/paper/b20650dc95596158ce942ab4b7852f57b96d473d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Neurology
Citations in the corpus
- Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis (2020, neutral): “2020 [26] China/Guangzhou retrospective study from January 23, 2020, and February 4, 2020 90 M = 39 (43%) F = 51 (57%) 50 (18–86) NA 1 (1%) NA NA NA NA”
- The epidemiology, diagnosis and treatment of COVID-19 (2020, methodology): “Combining asessment of imaging features with clinical and laboratory findings ould facilitate early diagnosis of COVID-19 pneumonia [38-40] .”
- Coronavirus (COVID-19) (2020, background): “One series reported 72% of cases with ground glass appearance, 12% with consolidation, 12% with crazy paving patterns, 37% with interlobular thickening, 56% with adjacent pleural thickening, and 61% with linear opacities [95].”
- SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract (2020, positive): “Aspiration of SARS-CoV-2 into the lung is consistent with the patchy, bibasilar infiltrates observed by chest CT in COVID-19 (Xu et al., 2020).”